4-1BB作为共刺激因子结构域(co-stimulatory domains,CD)被广泛用于CAR-T细胞治疗。 CAR-T(嵌合抗原受体T)细胞,具有针对癌细胞的定向特异性,是一种很有前景的治疗癌症的方法。目前全球已有6款CAR-T产品上市。4-1BB广泛应用于CAR-T产品的结构设计,诺华的Kymriah的共刺激结构域是4-1BB。作为CAR-T细胞的胞内共刺...
1. CD137 + T-Cells: Protagonists of the Immunotherapy Revolution.Cancers (Basel). 2021 Jan 26;13(3):456. 2.An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int JMol Sci. 2019 Apr; 20(8): 1822. 3.Immunotherapy targeting 4-1BB...
随后的荧光共聚焦和胞膜蛋白印迹实验证实A20在4-1BB CAR-T细胞膜上显著积聚;而在TRAF结合位点突变的4-1BB CAR-T细胞中(以删除4-1BB羧基端最后十个氨基酸的BBζ ΔC10细胞为代表),这一效应明显消除。使用RNA-seq对比在抗原激活...
[2] Guedan, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI insight, 2018.[3] Ying Wang, et al. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. Cytotherapy, ...
1. CD137 + T-Cells: Protagonists of the Immunotherapy Revolution.Cancers (Basel). 2021 Jan 26;13(3):456. 2.An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int JMol Sci. 2019 Apr; 20(8): 1822. 3.Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, ...
Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011 Jul;8(4):281-4. Bartkowiak T, Curran MA. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol. 2015 Jun 8;5:117. Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-...
Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. Cytotherapy, 2021. [4] Cheuk, Mufti, and Guinn. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Therapy, 2004...
[3]Engineered T cells: The promise and challenges of cancer immunotherapy[J]. Nature reviews. Cancer, 2016, 16(9):566-581. [4] Chester C , Sanmamed M F , Wang J , et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies[J]. Blood, 2017:...
Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011 Jul;8(4):281-4. Bartkowiak T, Curran MA. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol. 2015 Jun 8;5:117. Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-...
[1]. Yuan Zhao ,et al. Dispensable Role for 4-1BB and 4-1BBL in Development of Vaccinia Virus-Specific CD8 T Cells. Immunol Lett. 2012 Jan 30;141(2):220-6. [2]. Li Y, et al. Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. ...